In a recent ruling by the United States Court of Federal Claims, BiotechInnova, LLC's lawsuit against the U.S. government was partially dismissed. The court's decision affects BiotechInnova's claims regarding payments related to a contract for COVID-19 masks. The ruling highlights the complexities of contract assignments and the obligations of government contractors.

The case, BiotechInnova, LLC v. United States, was filed under docket number 24-1194 on August 26, 2026. The court, presided over by Judge Ryan T. Holte, addressed the dispute stemming from a contract awarded to Wright Construction Group for the procurement of one million N95 masks during the COVID-19 pandemic.

Background

The parties involved in this case are BiotechInnova, LLC, a mask supplier, and the United States government. The dispute arose when the Federal Bureau of Prisons (BOP) awarded a contract to Wright Construction Group for the delivery of N95 masks. Wright initially intended to supply 3M-brand masks but faced delays due to high demand. In June 2020, Wright proposed using masks from BiotechInnova as an alternative.

However, when BiotechInnova's masks were delivered in July 2020, they were found to be non-compliant with the contract's requirement for NIOSH-approved masks. Consequently, the BOP rejected the masks and terminated the contract. BiotechInnova claimed that it had an assignment of contract proceeds from Wright but that the government still paid Wright after the masks were rejected. This led BiotechInnova to file a lawsuit against the government for wrongful payment, as well as claims against Wright for breach of contract.

The Ruling

The court ruled on the government's combined motion to dismiss and motion for summary judgment. Judge Holte found that the claims against Wright, a private entity, were beyond the court's jurisdiction. The court stated, "the suit as to them must be ignored as beyond the jurisdiction of the court." Thus, the claims against Wright were dismissed.

However, the court did not dismiss all of BiotechInnova's claims against the government. The judge addressed the validity of the assignment of contract proceeds to BiotechInnova and whether the government had waived the requirements of the Anti-Assignment Act. The court noted, "the totality of the circumstances presented to the court establishes the Government’s recognition of the assignments by its knowledge, assent, and action consistent with the terms of the assignments." This aspect of the ruling allows BiotechInnova's claims against the government to proceed.

Impact

This ruling has significant implications for BiotechInnova as it continues its legal battle with the government over the contract payments. The dismissal of claims against Wright means that BiotechInnova cannot pursue its breach of contract claims against the prime contractor in this court. However, the court's recognition of the assignment of proceeds suggests that BiotechInnova may still have a path to recover funds from the government.

The decision also highlights the importance of understanding the complexities of contract assignments in government procurement. It underscores the necessity for contractors to ensure compliance with assignment regulations and to maintain clear communication with government entities regarding contract modifications and assignments.

What's Next

BiotechInnova may continue to pursue its claims against the government in the Court of Federal Claims. The dismissal of claims against Wright does not prevent BiotechInnova from seeking remedies in other legal forums, including ongoing litigation in Florida state court. The outcome of this case could set important precedents regarding contract assignments and the responsibilities of government contractors.